Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nature18929 http://scihub22266oqcxt.onion/10.1038/nature18929 C5034582!5034582!27338952     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2016 ; 535 (7613): 556-60 Nephropedia Template TP {{tp|p=27338952|t=2016. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption |pdf=|usr=}}{{27338952}} gab.com Text HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=27338952 #FOAvip Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env1, in the setting of analytical treatment interruption in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled. Two or four 30 mg kg?1 infusions of 3BNC117, separated by 3 or 2 weeks, respectively, are generally well tolerated. Infusions are associated with a delay in viral rebound for 5?9 weeks after two infusions, and up to 19 weeks after four infusions, or an average of 6.7 and 9.9 weeks respectively, compared with 2.6 weeks for historical controls (P < 0.00001). Rebound viruses arise predominantly from a single provirus. In most individuals, emerging viruses show increased resistance, indicating escape. However, 30% of participants remained suppressed until antibody concentrations waned below 20 ?g ml?1, and the viruses emerging in all but one of these individuals showed no apparent resistance to 3BCN117, suggesting failure to escape over a period of 9?19 weeks. We conclude that administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during analytical treatment interruption in humans. Twit Text FOAVip HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=27338952 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27338952 #FOAvip English Wikipedia <ref>{{Cite pmid|27338952}}</ref> HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption #MMPMID27338952 Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JCC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M Nature 2016[Jul]; 535 (7613): 556-60 PMID27338952show ga Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env1, in the setting of analytical treatment interruption in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled. Two or four 30 mg kg?1 infusions of 3BNC117, separated by 3 or 2 weeks, respectively, are generally well tolerated. Infusions are associated with a delay in viral rebound for 5?9 weeks after two infusions, and up to 19 weeks after four infusions, or an average of 6.7 and 9.9 weeks respectively, compared with 2.6 weeks for historical controls (P < 0.00001). Rebound viruses arise predominantly from a single provirus. In most individuals, emerging viruses show increased resistance, indicating escape. However, 30% of participants remained suppressed until antibody concentrations waned below 20 ?g ml?1, and the viruses emerging in all but one of these individuals showed no apparent resistance to 3BCN117, suggesting failure to escape over a period of 9?19 weeks. We conclude that administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during analytical treatment interruption in humans. äHIV-1 antibody 3BNC117 suppresses viral rebound in humans during treat(epmc).pdf DeepDyve Pubget Overpricing